Navigation Links
OxThera startar klinisk studie inom Primär Hyperoxaluri
Date:1/8/2014

et enda tillgängliga potentiella botemedlet en kombinerad transplantation av lever och njure.

OxThera innehar ägenderättigheter till farmaceutiska beredningar samt dessas användning för behandling av hyperoxaluri. Oxabact® betingar särläkemedelsstatus i EU och USA för behandling av PH.

Om OxThera  OxThera innehar globala rättigheter för beredningar samt dessas användning för behandling av hyperoxaluri. OxThera har två produkter under utveckling: Oxabact® för behandling av Primär Hyperoxaluri, och Oxazyme®, ett oxalatdekarboxylas, för behandling av oxalatmalabsorption och njurkollaps vid enterisk hyperoxaluri.

För ytterligare information, var vänlig kontakta: Elisabeth Lindner, VD OxThera AB, telefon +46-8-660-0223

http://www.oxthera.com



'/>"/>
SOURCE OxThera AB
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. OxThera coordonne le projet Elimox du 7e PC - 2,19 millions EUR dédiés au développement dun médicament pour traiter lhyperoxalurie
2. OxThera stärker patentportfölj för särläkemedel - Primär hyperoxaluri
3. OxThera stärkt sein Patentportfolio für primäre Hyperoxalurie, eine seltene Krankheit
4. OxThera Strengthens Patent Portfolio for Orphan Disease - Primary Hyperoxaluria
5. RNL BIO Co. Ltd. lämnar in IND-ansökan om att påbörja klinisk fas II-prövning av RNL-JointStem för artros i USA
6. RNL BIO har anmält en fas II/III klinisk prövning till KFDA för en behandling av cerebral pares med autologa stamceller framställda från fettvävnad
7. ideaPoint Inc. präsentiert Multi-Sponsor-Portal für Forscheranfragen an fünf globale Studiensponsoren bezüglich Zugang zu Daten aus klinischen Studien
8. CMC Biologics and OncoSynergy Enter into Agreement to Develop and Manufacture Material for IND Enabling Studies and Phase I Clinical Trials
9. Berg startet bisher erste klinische Stratified-Medicine-Studie zur Untersuchung des Krebsstoffwechsels solider Tumoren
10. Sangamo BioSciences Presents Clinical Data From Key SB-728-T HIV Studies: Proof Of Concept For Ongoing Sustained Functional Control Of HIV Viral Load; Cytoxan Preconditioning Successfully Enhances Engraftment
11. Lilly Announces Edivoxetine Did Not Meet Primary Endpoint of Phase III Clinical Studies as Add-On Therapy for Major Depressive Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  Cleave Biosciences today announced ... has granted the company a key patent providing ... molecule CB-5083. This newly issued patent, ... p97," U.S. 9,062,026, allows for claims on the ... selective oral inhibitor of p97, a critical enzyme ...
(Date:7/30/2015)... ATLANTA , July 30, 2015  Alimera Sciences, ... that specializes in the research, development and commercialization of ... its second quarter fiscal year 2015 financial results after ... investor conference call will follow on the same day ... Myers , President and Chief Executive Officer, and ...
(Date:7/30/2015)... Mass., July 30, 2015   HeartWare International, ... innovator of less invasive, miniaturized circulatory support technologies ... failure, today announced total revenue of $73.6 million ... to $70.1 million for the quarter ended June ... approximately $6.0 million, or nine percentage points, during ...
Breaking Medicine Technology:Alimera Sciences To Release Second Quarter Fiscal Year 2015 Financial Results 2HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 2HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 3HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 4HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 5HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 6HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 7HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 8HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 9HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 10HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 11HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 12HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 13HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 14
... Sept. 19 A single dose of ... resulted in favorable changes in hemodynamics associated ... patients with advanced heart,failure (ADHF) who participated ... on HemodynamIc Parameters in Subjects with HEart ...
... (http://www.fbcx.com ) today announced that, following the results ... an animal study at the,National Institutes of Health, FBCx ... center. The largest study to date on the,patented all- ... but not obese individuals. "Our earlier study with ...
Cached Medicine Technology:ECLIPSE Data on Effects of Otsuka's Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients' Hemodynamics and Urine Output Featured in Heart Failure Society of America's Late Breaking Trials 2ECLIPSE Data on Effects of Otsuka's Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients' Hemodynamics and Urine Output Featured in Heart Failure Society of America's Late Breaking Trials 3ECLIPSE Data on Effects of Otsuka's Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients' Hemodynamics and Urine Output Featured in Heart Failure Society of America's Late Breaking Trials 4ArtJen Announces Major Clinical Trial of Its Patented Weight Loss Product FBCx 2
(Date:7/30/2015)... ... 30, 2015 , ... The American Association of Poison Control ... the reinstitution of National Prescription Drug Take-Back Days. The 10th event of this ... 2:00 PM local time. On the 26th, the DEA, with the assistance of ...
(Date:7/30/2015)... ... ... InventHelp, a leading inventor service company, announces that one of its ... to apply lotion or medication to a hard-to-reach area. This invention is patented. , ... to the back, and provides thorough coverage. The product would prevent the user from ...
(Date:7/30/2015)... ... 30, 2015 , ... Political unrest is the number one ... new survey by leading international insurance provider Clements Worldwide. The "Clements Worldwide Risk ... the largest sources of financial losses among respondents. , Twenty-eight percent of top ...
(Date:7/30/2015)... ... July 30, 2015 , ... WellSpan ... administrative contractor (MAC) over submitted claims for bariatric surgery that, despite complying with ... program integrity, Becky Dennis, a nurse auditor at WellSpan Health, tells Atlantic Information ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... At the presentation of the 2015 Annual ... was focused on research presented by the Journal of Arthroplasty pertaining to how ... like driving. , Results of the study confirm what Santa Rosa Orthopaedics (SRO) ...
Breaking Medicine News(10 mins):Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3Health News:InventHelp® Client Patents “My Back Buddy” – Device Could Apply Lotion to Hard-to-Reach Areas Easily 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 3Health News:Hospital Details Fight for Bariatric Surgery Reimbursement in AIS Newsletter 2Health News:Hospital Details Fight for Bariatric Surgery Reimbursement in AIS Newsletter 3Health News:SRO Surgeon Dr. Nathan Ehmer Backs Up Latest Study That Total Hip Replacement Surgery Patients Are Resuming Normal Activities Sooner 2Health News:SRO Surgeon Dr. Nathan Ehmer Backs Up Latest Study That Total Hip Replacement Surgery Patients Are Resuming Normal Activities Sooner 3
... the teenagers who suffer from eating disorders do not reveal it ... for over six months. As many as 1,000 youngsters were studied, ... are capable of recognizing such disorders in their children, while only ... parents. ,The research was conducted by the Eating ...
... Geneva University Hospital, tested the new technique of methicillin-resistant ... ,He said that it could reduce // ... the money spent in order to deal with these ... bacteria DNA in the patient swabs. ,This ...
... has highlighted a new combination drug treatment for asthma ... even restore normal breathing in affected individuals. // ... findings, the results of which can soon to integrated ... is believed to enhance airway function by the inhibition ...
... Hong Kong have been put on high alert following the ... poultry. // The officials have been instructed to keep a ... the territory. ,The proposed move has also strengthened ... The health chief of the former British colony, York Chow ...
... the Mental Health Foundation, even as the UK seeks to win the ... to find out how much importance men give to the game. Evaluations ... to lose their jobs just for the pleasure of watching the game, ... by others, or participate in the game itself. ,The ...
... could be a common gene which gives rise to Alzheimer's ... School of Medicine. This could also serve to conclusively prove ... from about 1,000 families in which the Alzheimer's disease is ... genetic link with regard to the disease was sought to ...
Cached Medicine News:Health News:Eating Disorders Among Children Are Widespread 2Health News:Bird Flu Threat Prompts Tightened Security Across Hong Kong Border 2
Liquichek CK/LD Isoenzyme Control features analytes used in cardiac profile testing and protein electrophoresis. Assayed for most methods including instruments, immunoinhibition kits and electrophore...
Lyphochek Hemostasis Control is a multi-analyte control to help monitor coagulation factor assays and selected thrombosis risk assays. Assayed values are available for most major instrumentation....
Meter Trax Control is a whole blood quality control that can be used for glucose, hemoglobin and hematocrit testing on point of care instruments....
... intended for use in assessing compliance ... including chain of custody, for Federal ... the Substance Abuse and Mental Health ... Services Department (HHS) and other federal ...
Medicine Products: